223 related articles for article (PubMed ID: 25762642)
1. Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer.
Tao J; Ji J; Li X; Ding N; Wu H; Liu Y; Wang XW; Calvisi DF; Song G; Chen X
Oncotarget; 2015 Mar; 6(9):6977-88. PubMed ID: 25762642
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma.
Komoll RM; Hu Q; Olarewaju O; von Döhlen L; Yuan Q; Xie Y; Tsay HC; Daon J; Qin R; Manns MP; Sharma AD; Goga A; Ott M; Balakrishnan A
J Hepatol; 2021 Jan; 74(1):122-134. PubMed ID: 32738449
[TBL] [Abstract][Full Text] [Related]
3. C-Myc-dependent repression of two oncogenic miRNA clusters contributes to triptolide-induced cell death in hepatocellular carcinoma cells.
Li SG; Shi QW; Yuan LY; Qin LP; Wang Y; Miao YQ; Chen Z; Ling CQ; Qin WX
J Exp Clin Cancer Res; 2018 Mar; 37(1):51. PubMed ID: 29523159
[TBL] [Abstract][Full Text] [Related]
4. ANT2 suppression by shRNA restores miR-636 expression, thereby downregulating Ras and inhibiting tumorigenesis of hepatocellular carcinoma.
Jang JY; Lee YS; Jeon YK; Lee K; Jang JJ; Kim CW
Exp Mol Med; 2013 Jan; 45(1):e3. PubMed ID: 23306701
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-494 within an oncogenic microRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer.
Lim L; Balakrishnan A; Huskey N; Jones KD; Jodari M; Ng R; Song G; Riordan J; Anderton B; Cheung ST; Willenbring H; Dupuy A; Chen X; Brown D; Chang AN; Goga A
Hepatology; 2014 Jan; 59(1):202-15. PubMed ID: 23913442
[TBL] [Abstract][Full Text] [Related]
6. Critical role of Myc activation in mouse hepatocarcinogenesis induced by the activation of AKT and RAS pathways.
Xin B; Yamamoto M; Fujii K; Ooshio T; Chen X; Okada Y; Watanabe K; Miyokawa N; Furukawa H; Nishikawa Y
Oncogene; 2017 Sep; 36(36):5087-5097. PubMed ID: 28481866
[TBL] [Abstract][Full Text] [Related]
7. SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice.
Delogu S; Wang C; Cigliano A; Utpatel K; Sini M; Longerich T; Waldburger N; Breuhahn K; Jiang L; Ribback S; Dombrowski F; Evert M; Chen X; Calvisi DF
Oncotarget; 2015 Feb; 6(4):2222-34. PubMed ID: 25537506
[TBL] [Abstract][Full Text] [Related]
8. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
9. SCD1 Expression is dispensable for hepatocarcinogenesis induced by AKT and Ras oncogenes in mice.
Li L; Wang C; Calvisi DF; Evert M; Pilo MG; Jiang L; Yuneva M; Chen X
PLoS One; 2013; 8(9):e75104. PubMed ID: 24069385
[TBL] [Abstract][Full Text] [Related]
10. AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways.
Ho C; Wang C; Mattu S; Destefanis G; Ladu S; Delogu S; Armbruster J; Fan L; Lee SA; Jiang L; Dombrowski F; Evert M; Chen X; Calvisi DF
Hepatology; 2012 Mar; 55(3):833-45. PubMed ID: 21993994
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal regulation of microRNA-122 and c-Myc in hepatocellular cancer: role of E2F1 and transcription factor dimerization partner 2.
Wang B; Hsu SH; Wang X; Kutay H; Bid HK; Yu J; Ganju RK; Jacob ST; Yuneva M; Ghoshal K
Hepatology; 2014 Feb; 59(2):555-66. PubMed ID: 24038073
[TBL] [Abstract][Full Text] [Related]
12. MiR-214 inhibits cell growth in hepatocellular carcinoma through suppression of β-catenin.
Wang X; Chen J; Li F; Lin Y; Zhang X; Lv Z; Jiang J
Biochem Biophys Res Commun; 2012 Nov; 428(4):525-31. PubMed ID: 23068095
[TBL] [Abstract][Full Text] [Related]
13. miR-122 regulates tumorigenesis in hepatocellular carcinoma by targeting AKT3.
Nassirpour R; Mehta PP; Yin MJ
PLoS One; 2013; 8(11):e79655. PubMed ID: 24244539
[TBL] [Abstract][Full Text] [Related]
14. Crosstalk between liver-related microRNAs and Wnt/β-catenin pathway in hepatocellular carcinoma patients.
Ashmawy AM; Elgeshy KM; Abdel Salam ET; Ghareeb M; Kobaisi MH; Amin HAA; Sharawy SK; Abdel Wahab AHA
Arab J Gastroenterol; 2017 Sep; 18(3):144-150. PubMed ID: 28958640
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma.
Huang JY; Zhang K; Chen DQ; Chen J; Feng B; Song H; Chen Y; Zhu Z; Lu L; De W; Wang R; Chen LB
Oncotarget; 2015 Jul; 6(21):18613-30. PubMed ID: 26164082
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.
Rivas MA; Venturutti L; Huang YW; Schillaci R; Huang TH; Elizalde PV
Breast Cancer Res; 2012 May; 14(3):R77. PubMed ID: 22583478
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of microRNA-30a-5p inhibits liver cancer cell proliferation and induces apoptosis by targeting MTDH/PTEN/AKT pathway.
Li WF; Dai H; Ou Q; Zuo GQ; Liu CA
Tumour Biol; 2016 May; 37(5):5885-95. PubMed ID: 26589417
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-493-5p-mediated repression of the MYCN oncogene inhibits hepatic cancer cell growth and invasion.
Yasukawa K; Liew LC; Hagiwara K; Hironaka-Mitsuhashi A; Qin XY; Furutani Y; Tanaka Y; Nakagama H; Kojima S; Kato T; Ochiya T; Gailhouste L
Cancer Sci; 2020 Mar; 111(3):869-880. PubMed ID: 31883160
[TBL] [Abstract][Full Text] [Related]
19. Eukaryotic Initiation Factor 5A2 Contributes to the Maintenance of CD133(+) Hepatocellular Carcinoma Cells via the c-Myc/microRNA-29b Axis.
Bai HY; Liao YJ; Cai MY; Ma NF; Zhang Q; Chen JW; Zhang JX; Wang FW; Wang CY; Chen WH; Jin XH; Xu RH; Guan XY; Xie D
Stem Cells; 2018 Feb; 36(2):180-191. PubMed ID: 29119708
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways.
Wang C; Delogu S; Ho C; Lee SA; Gui B; Jiang L; Ladu S; Cigliano A; Dombrowski F; Evert M; Calvisi DF; Chen X
J Hepatol; 2012 Sep; 57(3):577-83. PubMed ID: 22617155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
